PHILOGEN
Updates & Highlights
Number of shareholders of Philogen SpA – LSX:A2QQB6
Number of shareholders of Philogen SpA – LSX:A2QQB6
TradingView · 5 days ago
Dividend history of Philogen, Dividend date of Philogen, Dividend data of Philogen, Dividend Calendar of Philogen
Dividend history of Philogen, Dividend date of Philogen, Dividend data of Philogen, Dividend Calendar of Philogen
RTTNews · 19 days ago
Philogen ends Q1 with declining NFP; share buyback launched
Philogen ends Q1 with declining NFP; share buyback launched
marketscreener.com · 25 days ago
Recent Openings
View all 1 jobsCulture & Mission
Benefits & Perks
Competitive Salary
Market-rate compensation
Health Insurance
Medical, dental & vision
Learning Budget
Professional development
Equity/Stock Options
Ownership in the company
Remote Work
Work from anywhere flexibility
Generous PTO
Paid time off
Tech Stack
Core Values
Innovation
Pushing boundaries in AI/ML technology
Collaboration
Working together to achieve more
Excellence
Striving for the highest quality
Impact
Making a difference in the world
Office Locations
Team
Are you on the team at PHILOGEN?
Claim this company page to verify ownership, edit details, and respond to applicants.
Claim this company →News & Press
20 recentNumber of shareholders of Philogen SpA – LSX:A2QQB6
Number of shareholders of Philogen SpA – LSX:A2QQB6
TradingView · 5 days ago
Dividend history of Philogen, Dividend date of Philogen, Dividend data of Philogen, Dividend Calendar of Philogen
Dividend history of Philogen, Dividend date of Philogen, Dividend data of Philogen, Dividend Calendar of Philogen
RTTNews · 19 days ago
Philogen ends Q1 with declining NFP; share buyback launched
Philogen ends Q1 with declining NFP; share buyback launched
marketscreener.com · 25 days ago
Philogen Details Voting Rights Structure Ahead of April 29 Shareholders’ Meeting
Philogen Details Voting Rights Structure Ahead of April 29 Shareholders’ Meeting
TipRanks · about 2 months ago
Sun Pharma Partner Philogen Reports Mixed Phase II Results, Plans Registrational Studies
Sun Pharma Partner Philogen Reports Mixed Phase II Results, Plans Registrational Studies
scanx.trade · 2 months ago
PHILOGEN S.p.A. - 2025 10 06 - CS settimanale acquisto azioni proprie
PHILOGEN S.p.A. - 2025 10 06 - CS settimanale acquisto azioni proprie
TradingView · 8 months ago
Philogen withdraws MAA for Nidlegy in EU
Philogen withdraws MAA for Nidlegy in EU
The Pharma Letter · 11 months ago
Sun Pharma partner Philogen withdraws EU application for skin cancer drug
Sun Pharma partner Philogen withdraws EU application for skin cancer drug
Business Standard · 12 months ago
Sun Pharma European partner Philogen pulls EMA application for skin cancer drug Nidlegy
Sun Pharma European partner Philogen pulls EMA application for skin cancer drug Nidlegy
Medical Dialogues · 12 months ago
Sun Pharma, Philogen Ink Global Commercialization Deal for Fibromun, an Anti-Cancer Immunotherapy
Sun Pharma, Philogen Ink Global Commercialization Deal for Fibromun, an Anti-Cancer Immunotherapy
Pharmaceutical Executive · over 1 year ago
EMA validates Philogen-Sun Pharma's MAA for melanoma therapy
EMA validates Philogen-Sun Pharma's MAA for melanoma therapy
Pharmaceutical Technology · almost 2 years ago
Philogen
Philogen
The Pharma Letter · almost 2 years ago
Philogen and Sun Pharma seek EMA approval for melanoma therapy
Philogen and Sun Pharma seek EMA approval for melanoma therapy
Yahoo Finance · about 2 years ago
Philogen and Sun Pharma seek EMA approval for melanoma therapy
Philogen and Sun Pharma seek EMA approval for melanoma therapy
Pharmaceutical Technology · about 2 years ago
Sun Pharma and Philogen Sign Exclusive Agreement for NIDLEGY™ Commercialization in Europe, Australia, and New Zealand
Sun Pharma and Philogen Sign Exclusive Agreement for NIDLEGY™ Commercialization in Europe, Australia, and New Zealand
BioPharma APAC · about 3 years ago
Sun Pharma, Philogen sign licence agreement for Nidlegy
Sun Pharma, Philogen sign licence agreement for Nidlegy
Pharmaceutical Technology · about 3 years ago
Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand
Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand
PR Newswire · about 3 years ago
Philogen SpA - Notice of Full Year 2021 Results
Philogen SpA - Notice of Full Year 2021 Results
Newswire.com · about 4 years ago
White & Case Advises Philogen on First Italian Main Market IPO of 2021
White & Case Advises Philogen on First Italian Main Market IPO of 2021
White & Case LLP · over 5 years ago
Italian cancer startup Philogen gets off an impressive $70M funding round
Italian cancer startup Philogen gets off an impressive $70M funding round
Fierce Biotech · about 7 years ago